GlassScriptPhysician profile
Alok P Pasricha
NPI 1053359661
$80,924.37
in general payments reported to CMS, 2019-2025
63 companies · $3,882 in 2025
The $3,882 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $6,694 · 2021: $10K · 2022: $23K · 2023: $8,060 · 2024: $3,021 · 2025: $3,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,875 · Honoraria: $3,413 · Travel and Lodging: $735 · Consulting Fee: $716 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,874.88 |
| Honoraria | $3,412.50 |
| Travel and Lodging | $735.17 |
| Consulting Fee | $715.50 |
| Education | $224.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23,348.10 | 2020-2023 | Acthar |
| Mallinckrodt Enterprises LLC | $21,602.35 | 2019 | |
| Ani Pharmaceuticals, INC. | $6,475.91 | 2021-2025 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $3,787.35 | 2020-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $2,237.61 | 2019-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $2,119.74 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $1,825.31 | 2022-2025 | |
| Biogen, INC. | $1,622.05 | 2019-2025 | Vumerity, Plegridy, Skyclarys |
| Ucb, INC. | $1,585.59 | 2019-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $1,260.10 | 2020-2025 | |
| Abbvie INC. | $1,064.35 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,010.24 | 2020-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $989.56 | 2019-2022 | |
| Csl Behring | $856.48 | 2019-2025 | Hizentra |
| Lilly USA, LLC | $853.17 | 2019-2025 | Emgality, Kisunla, Reyvow |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $786.05 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $783.61 | 2019-2021 | |
| Amgen INC. | $634.04 | 2019-2023 | Aimovig |
| Pfizer INC. | $614.86 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $605.76 | 2020-2024 | Onzetra Xsail, Nexletol, Contrave |
| Livanova USA, INC. | $578.36 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $530.77 | 2019-2025 | Vyepti, Rexulti |
| Kyowa Kirin, INC. | $498.54 | 2020-2025 | Nourianz |
| Grifols USA, LLC | $388.46 | 2019-2025 | Gamunex-C |
| Celgene Corporation | $367.00 | 2021-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $361.43 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $279.80 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $275.12 | 2023-2024 | Aptiom |
| Janssen Pharmaceuticals, INC | $263.09 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $234.45 | 2021 | |
| Corium, LLC | $225.66 | 2022-2023 | Adlarity |
| Impel Pharmaceuticals INC. | $218.40 | 2022-2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $185.46 | 2019-2025 | Rytary, Crexont |
| E.R. Squibb & Sons, L.L.C. | $168.49 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $168.19 | 2022 | |
| Ge Healthcare | $166.72 | 2023-2025 | |
| Acorda Therapeutics, INC | $164.96 | 2019-2022 | |
| Genentech USA, INC. | $155.91 | 2019-2023 | Ocrevus |
| Avion Pharmaceuticals | $150.42 | 2021-2023 | Methylphenidate Hydrochloride |
| Teleflex LLC | $139.37 | 2025 | Deknatel |
| Genzyme Corporation | $124.88 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $124.68 | 2024-2025 | Horizant |
| Avanir Pharmaceuticals, INC. | $118.54 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $103.98 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $102.40 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $98.40 | 2024-2025 | Xeomin, Inbrija |
| Argenx US, INC. | $96.05 | 2022-2023 | Vyvgart Hytrulo, Vyvgart |
| Jazz Pharmaceuticals INC. | $90.01 | 2022-2023 | |
| Kerecis Limited | $86.06 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Axsome Therapeutics, INC. | $72.35 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $60.24 | 2023-2024 | Rexulti, Nuedexta |
| Allergan, INC. | $57.28 | 2020 | |
| Sanofi-Aventis U.S. LLC | $37.37 | 2021 | |
| Akcea Therapeutics, INC. | $24.90 | 2020 | |
| Kedrion Biopharma, INC. | $22.14 | 2024 | Koate, Albuked, Kedrab |
| Intra-Sana Laboratories | $21.84 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Astrazeneca Pharmaceuticals LP | $17.34 | 2024 | Wainua |
| Neuronetics, INC. | $16.54 | 2019 | |
| Medtronic USA, INC. | $14.98 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.30 | 2019 | |
| Almatica Pharma LLC | $12.70 | 2021 | |
| Abbott Laboratories | $12.63 | 2022 | |
| Zyla Life Sciences, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Pasricha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.